HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

La Roche-Posay for skin cancer prevention

This article was originally published in The Rose Sheet

Executive Summary

This month, La Roche-Posay is donating a portion of the proceeds - up to a total of $10,000 - from sales of Anthelios SX Daily Moisturizing Cream with SPF 15 to The Skin Cancer Foundation, according to a June 4 release. "As the makers of a new sun-care product, we felt it was fundamental to support The Skin Care Foundation in their efforts to educate the public about the dangers of skin cancer and the steps that can be taken to help prevent ... the fastest-growing cancer in the U.S.," Yannick Raynaud, VP-marketing and medical detailing, states. Formulated with the Mexoryl SX organic, highly photo-stable sun filter for protection against short UVA waves for long periods of time, Anthelios SX is the first sunscreen formula to be approved by FDA since 1988, La Roche-Posay says (1"The Rose Sheet" May 21, 2007, In Brief)...
Advertisement

Related Content

La Roche-Posay donates sunscreen
Anthelios expands to CVS
Advertisement
UsernamePublicRestriction

Register

RS014770

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel